Sign Out
The recommended starting dose is 7.5 mg daily. The dose may be increased to 15 mg daily, based on individual response, 2 weeks after therapy is initiated. It is taken with or without regards to food. The tablet must be swallowed whole, and not chewed, divided or crushed.
Pediatric Population: The safety and effectiveness of Darifenacin in pediatric patients have not been established.
Geriatric Use: No overall differences in safety and efficacy were observed between patients over 65 years and younger patients <65 years. No dose adjustment is recommended for elderly patients.
Renal impairment: No dose adjustment is required in patients with impaired renal function. However, caution should be exercised when treating this population.
Hepatic impairment: For patients with moderate hepatic impairment (Child-Pugh B) or when co-administered with potent CYP3A4 inhibitors, the daily dose should not exceed 7.5 mg daily. Darifenacin is not recommended for use in patients with severe hepatic impairment (Child-Pugh C).
